Evofem Biosciences, Inc.EVFMOTCMARKET
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank94
3Y CAGR+42.2%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+42.2%/yr
Quarterly compound
Percentile
P94
Near historical high
vs 3Y Ago
2.9x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 111.51% |
| Q2 2025 | -621.25% |
| Q1 2025 | 123.26% |
| Q4 2024 | -424.62% |
| Q3 2024 | 59.77% |
| Q2 2024 | -1027.64% |
| Q1 2024 | 172.35% |
| Q4 2023 | 92.81% |
| Q3 2023 | -58.23% |
| Q2 2023 | 69.76% |
| Q1 2023 | 24.36% |
| Q4 2022 | 60.76% |
| Q3 2022 | 38.74% |
| Q2 2022 | -27.73% |
| Q1 2022 | 1.07% |
| Q4 2021 | 42.58% |
| Q3 2021 | 30.92% |
| Q2 2021 | -57.12% |
| Q1 2021 | 12.16% |
| Q4 2020 | -7.97% |
| Q3 2020 | -139.70% |
| Q2 2020 | -0.68% |
| Q1 2020 | -11.21% |
| Q4 2019 | 7.90% |
| Q3 2019 | 28.00% |
| Q2 2019 | -166.19% |
| Q1 2019 | 25.07% |
| Q4 2018 | -14.77% |
| Q3 2018 | 53.47% |
| Q2 2018 | -5.78% |
| Q1 2018 | -669.28% |
| Q4 2017 | 0.00% |
| Q3 2017 | 0.00% |
| Q2 2017 | 0.00% |
| Q1 2017 | 35.01% |
| Q4 2016 | 9.16% |
| Q3 2016 | 0.00% |